Summary
A European Parliament resolution calling for improved access to affordable medicines, increased transparency in drug pricing, and stronger measures against anti-competitive practices. 10 02.03.2017
Other
economy
taxation
environment
human rights
social policy
administrative law
public administration
business and competition
public finance and budget policy
Key points
- The resolution reaffirms that access to medicine is a fundamental human right and a core objective of EU health policy.
- There is a call for greater transparency regarding the costs of research and development, especially when public funds are involved.
- The document stresses the need to prevent medicine shortages by enforcing obligations on manufacturers and distributors.
- It calls for stricter monitoring of anti-competitive behaviors, such as 'pay for delay' agreements that block generic competition.
These raw data are provided by the Open Data Portal of the European Union (data.europa.eu) and are licensed under ODC-BY 1.0.